ClinicalTrials.gg
TerminatedNCT01136746HMHUpdated Nov 13, 2012Results posted

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin

A Phase 3 interventional study of Human regular insulin and Insulin lispro in Hyperglycemia, sponsored by Eli Lilly and Company. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-13.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing Insulin Glargine in Hyperglycemia — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Hyperglycemia.

Enrollment
13th of 15
16 · median 72
Started
2011
with 2 others
Phase 3
4 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
1 of 15
Eli Lilly and Company

Among the 15 studies testing Insulin Glargine in Hyperglycemia, this one is the 13th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 9th registered.

Hyperglycemia

802 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.

Browse Hyperglycemia studies →

Open to participants now

None of the 15 studies testing Insulin Glargine in Hyperglycemia is open now. The open studies under Hyperglycemia, anywhere →

Where they have run

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Insulin Glargine in Hyperglycemia as a file.
02

Study summary

The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.

Read the detailed description

This study involves a comparison of 2 methods for administering subcutaneous insulin therapy to non-critically ill adult patients with hyperglycemia and without known history of diabetes who are admitted to non-intensive care unit (ICU) general medical hospital services. Basal-bolus therapy, considered the gold standard for glucose control in patients with known diabetes, will be compared with sliding scale insulin, a commonly used method of glucose control (prevailing standard practice) in hospitalized patients. In this study, basal-bolus therapy will consist of once-daily glargine plus lispro 3 to 4 times daily adjusted to achieve pre-meal capillary plasma glucose \<140 milligrams per deciliter (mg/dL) and bedtime capillary plasma glucose \<180 mg/dL for patients who are eating [predose plasma glucose \<140 mg/dL for patients with nil per os (NPO) orders]; sliding scale insulin will be administered using human regular insulin 4 times daily as needed adjusted to achieve predose capillary plasma glucose target \<140 mg/dL in patients who are eating or have NPO orders.

03

Conditions studied

  • Hyperglycemia

Keywords

  • Hyperglycemia
  • Diabetes
  • Hospital
  • Diabetic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • No known history of diabetes
  • Admission or pre-entry plasma glucose (PG) level between 140 and 400 mg/dL
  • Non-critically ill and admitted to acute care medical services
  • Have a greater than or equal to 18.5 kg/m\^2 and less than or equal to 45 kilograms per square meter (kg/m\^2)

Major Exclusion Criteria:

  • Received any insulin/analog therapy for longer than 108 hours prior to study entry or intermediate- or long-acting insulin/analogs (neutral protamine Hagedorn, detemir, or glargine) in the 24 hours prior to randomization or any intravenous insulin therapy prior to randomization
  • Laboratory evidence of diabetic ketoacidosis for patients with pre-randomization PG greater than 250 mg/dL
  • Have taken any oral or injectable antihyperglycemic medications other than insulin within 3 months prior to study entry
  • Have acute critical illness or are expected to require admission to an ICU or equivalent or be treated with therapy during the hospital study period
  • Expected hospitalization less than 24 hours post-randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Sliding scale regular insulin

    Drug: Human regular insulin

  • Experimental
    Basal-bolus therapy

    Drug: Insulin lispro · Drug: Insulin glargine

Interventions

  • DrugInsulin, Regular, HumanStudies of Insulin, Regular, HumanInsulin, Regular, Human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)

    Also known as: Humulin R, LY041001

  • Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)

    Also known as: Humalog, LY275585

  • Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)

    Also known as: Lantus

06

What researchers measure

Primary outcomes

  1. Mean Plasma Glucose (MPG) Throughout Hospital Study Period

    Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  2. Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period

    Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

Secondary outcomes

  1. Mean Plasma Glucose (MPG) by Hospital Day

    The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7.

    Time frame: Day 1 up to day 7 of hospital study period

  2. Percentage of Plasma Glucose Measurements Within Range 71 to 179 mg/dL by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  3. Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL Throughout Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  4. Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  5. Mean Fasting Plasma Glucose (FPG) by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  6. Mean FPG Throughout Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  7. Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL Throughout the Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

  8. Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  9. Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL Throughout the Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

  10. Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  11. Percentage of Capillary PG Measurements >240 mg/dL Throughout the Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

  12. Percentage of Capillary PG Measurements >240 mg/dL by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  13. Total Daily Dose (TDD) of Insulin (Units) Throughout the Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

  14. TDD of Insulin (Units/kg) Throughout the Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

  15. TDD of Insulin (Units) by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  16. TDD of Insulin (Units/kg) by Hospital Day

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  17. Length of Hospital Stay Post-randomization Throughout the Hospital Study Period

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout the hospital study period (1 to 10 days post-randomization)

  18. Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period

    Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  19. Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), Throughout Hospital Study Period

    Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  20. Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, by Hospital Day

    Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  21. Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), by Hospital Day

    Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Day 1 up to day 10 of hospital study period

  22. Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period

    Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment. A summary of adverse events is located in the Reported Adverse Event Module.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  23. Percentage of Participants Requiring Intensive Care Unit Transfer

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  24. Percentage of Participants With Deterioration of Renal Function Throughout the Hospital Study Period

    Deterioration of renal function was defined by an increase in serum creatinine by \>0.5 milligrams per deciliter (mg/dL). Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  25. Percentage of Participants With Documented Nosocomial Infections

    Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

  26. Number of Participants With Major Adverse Cardiovascular Events (MACE)

    MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Due to low enrollment, this outcome measure was not analyzed.

    Time frame: Throughout hospital study period (1 to 10 days post-randomization)

07

Results

Posted Oct 12, 2012
Limitations and caveats
Due to low enrollment, this trial was terminated early, leading to small numbers of participants analyzed or some outcome measures not being able to be analyzed at all.

Participant flow

Participant flow — Overall Study
MilestoneSliding Scale Regular InsulinBasal-bolus Therapy
Started97
Completed64
Not completed33
Withdrew: Lost to follow-up02
Withdrew: Protocol violation21
Withdrew: Death10

Outcome measures

PrimaryMean Plasma Glucose (MPG) Throughout Hospital Study Period

Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)
Reported as:
Mean · milligrams per deciliter (mg/dL)
Mean Plasma Glucose (MPG) Throughout Hospital Study Period
milligrams per deciliter (mg/dL)Sliding Scale Regular InsulinBasal-bolus Therapy
Mean Plasma Glucose (MPG) Throughout Hospital Study Period167.6 ± 48.5128.4 ± 22.4
PrimaryPercentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period

Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)
Reported as:
Number · percentage of capillary PG measurements
Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period
percentage of capillary PG measurementsSliding Scale Regular InsulinBasal-bolus Therapy
Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period81.484.3
SecondaryMean Plasma Glucose (MPG) by Hospital Day

The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7.

Time frame:
Day 1 up to day 7 of hospital study period
Reported as:
Mean · mg/dL
Mean Plasma Glucose (MPG) by Hospital Day
mg/dLSliding Scale Regular InsulinBasal-bolus Therapy
Day 1 (n=6, n=6)178.1 ± 54.9149.9 ± 17.2
Day 2 (n=8, n=5)175.2 ± 57.9124.0 ± 29.8
Day 3 (n=6, n=3)151.0 ± 46.9128.5 ± 28.5
Day 4 (n=2, n=1)132.5 ± 2.1296.3 ± NA
Day 5 (n=1, n=1)154.8 ± NA104.6 ± NA
Day 6 (n=1, n=1)138.0 ± NA111.0 ± NA
Day 7 (n=0, n=1)NA ± NA108.0 ± NA
SecondaryPercentage of Plasma Glucose Measurements Within Range 71 to 179 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL Throughout Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryMean Fasting Plasma Glucose (FPG) by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryMean FPG Throughout Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryPercentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout the hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryPercentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout the hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryPercentage of Capillary PG Measurements >240 mg/dL Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout the hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryPercentage of Capillary PG Measurements >240 mg/dL by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryTotal Daily Dose (TDD) of Insulin (Units) Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout the hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryTDD of Insulin (Units/kg) Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout the hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryTDD of Insulin (Units) by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryTDD of Insulin (Units/kg) by Hospital Day

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryLength of Hospital Stay Post-randomization Throughout the Hospital Study Period

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout the hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryNumber (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)
Reported as:
Number · hypoglycemic episodes
Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period
hypoglycemic episodesSliding Scale Regular InsulinBasal-bolus Therapy
Hypoglycemic Episodes13
Severe Hypoglycemic Episodes00
SecondaryNumber of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), Throughout Hospital Study Period

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryNumber (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, by Hospital Day

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryNumber of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), by Hospital Day

Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Day 1 up to day 10 of hospital study period

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period

Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment. A summary of adverse events is located in the Reported Adverse Event Module.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period
participantsSliding Scale Regular InsulinBasal-bolus Therapy
Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period12
SecondaryPercentage of Participants Requiring Intensive Care Unit Transfer

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Deterioration of Renal Function Throughout the Hospital Study Period

Deterioration of renal function was defined by an increase in serum creatinine by \>0.5 milligrams per deciliter (mg/dL). Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Documented Nosocomial Infections

Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Major Adverse Cardiovascular Events (MACE)

MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Due to low enrollment, this outcome measure was not analyzed.

Time frame:
Throughout hospital study period (1 to 10 days post-randomization)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sliding Scale Regular Insulin—1/9 (11.1%)1/9 (11.1%)
Basal-bolus Therapy—0/7 (0%)2/7 (28.6%)
Most frequent serious events
Most frequent serious events
EventSliding Scale Regular InsulinBasal-bolus Therapy
Myocardial infarctionCardiac disorders1/90/7
Most frequent other events
Most frequent other events
EventSliding Scale Regular InsulinBasal-bolus Therapy
ConstipationGastrointestinal disorders1/91/7
High density lipoprotein decreasedInvestigations0/91/7

Baseline characteristics

Age Continuous
Age Continuous(years)Sliding Scale Regular InsulinBasal-bolus TherapyTotal
Mean60.2 ± 16.851.4 ± 8.556.4 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Sliding Scale Regular InsulinBasal-bolus TherapyTotal
Female527
Male459
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sliding Scale Regular InsulinBasal-bolus TherapyTotal
Hispanic or Latino101
Not Hispanic or Latino8715
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sliding Scale Regular InsulinBasal-bolus TherapyTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American527
White459
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Sliding Scale Regular InsulinBasal-bolus TherapyTotal
United States9716
08

Study locations

12 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Birmingham, Alabama 35294, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32209, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33136, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Weston, Florida 33331, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30312, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66604, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hazard, Kentucky 41701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangor, Maine 04401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kansas City, Missouri 64111, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cleveland, Ohio 44106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29425, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38104, United States
09

References and documents

Publications

  • Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005 May;28(5):1245-9. doi: 10.2337/diacare.28.5.1245. No abstract available. PubMed 15855602 ↗
  • American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010 Jan;33 Suppl 1(Suppl 1):S11-61. doi: 10.2337/dc10-S011. No abstract available. Erratum In: Diabetes Care. 2010 Mar;33(3):692. PubMed 20042772 ↗
  • Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009 May-Jun;15(4):353-69. doi: 10.4158/EP09102.RA. No abstract available. PubMed 19454396 ↗
  • Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007 Sep;30(9):2181-6. doi: 10.2337/dc07-0295. Epub 2007 May 18. PubMed 17513708 ↗
  • Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, Munoz C, Newton C, Peng L, Baldwin D. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009 Feb;94(2):564-9. doi: 10.1210/jc.2008-1441. Epub 2008 Nov 18. PubMed 19017758 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2010
First posted
Jun 3, 2010
Start
Mar 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Oct 12, 2012
Last update
Nov 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01136746
Responsible party
Sponsor
First posted
Jun 3, 2010
Start date
Mar 2011
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Oct 12, 2012
Last update
Nov 13, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Insulin Glargine

Start the discussion